Akros U.S. Tech 100 Protective Allocation Monthly Index

Next quarterly earnings for Q1 2027 are expected to be released around August 6, 2026, expected. Low impact is estimated as this is a routine scheduling announcement.

AppLovin's Q2 2026 earnings release is expected around August 5, 2026, based on past reporting schedules expected. Low impact estimated as the announcement of a date typically precedes the actual market-moving results.

Q2 2026 earnings release and conference call scheduled.

Q2 2026 earnings release on 2026-08-04, for which high importance is estimated due to potential 10% price impact, is scheduled.

Fiscal Q4 2026 earnings release on July 30, 2026, is expected to have a medium importance impact on the stock price, scheduled.

Apple's Q3 2026 earnings release is expected on July 30, 2026; analysts forecast an EPS of approximately $1.86 forecasted. Low importance is estimated as the market impact is expected to be around 1%.

Q3 2026 earnings release and conference call scheduled. Estimated > 10% impact as quarterly earnings are primary volatility drivers.

Microsoft's fiscal Q4 2026 earnings release and conference call are scheduled for July 29, 2026. Analysts forecast earnings of $4.21-$4.23 per share, which is estimated to have a 5% price impact based on historical volatility forecasted.

Q2 2026 earnings release on July 29, 2026; impact is estimated as Low as this is a standard scheduled announcement, expected.

NXP Semiconductors is scheduled to release its Q2 2026 financial results after market close on July 28, 2026, with analysts forecasting EPS around $3.50; a Medium impact is expected as earnings releases typically drive price volatility scheduled.

Alphabet's Q2 2026 earnings release is scheduled.

Q2 2026 earnings release expected; high importance due to potential for significant price movement following the report expected.

Texas Instruments Q2 2026 earnings release on 2026-07-22. The company forecasted revenue between $5.0B and $5.4B and EPS between $1.77 and $2.05. High importance estimated due to typical earnings volatility scheduled

Tesla's Q2 2026 earnings release is scheduled for July 22, 2026. Analysts forecast an EPS of approximately $0.42 to $0.45. A medium impact is estimated based on historical volatility, forecasted.

Q2 2026 earnings release is scheduled for 2026-07-22; analysts forecast EPS of $2.95, with a neutral impact estimated as the forecast is already public forecasted.

Q2 2026 earnings release on July 22, 2026. Low importance estimated as no market reaction has occurred yet; event is expected.

Intuitive Surgical's Q2 2026 earnings release, a major stock catalyst, is scheduled.

Netflix's Q2 2026 earnings release is scheduled for 2026-07-16. Analysts forecast EPS of $0.79 on revenue of $12.57 billion; High importance assigned based on historical earnings volatility often exceeding 10%, forecasted.

Abbott's Q2 2026 earnings release is scheduled for July 16, 2026. Analysts forecast EPS of $1.28. Medium importance estimated as earnings typically drive >5% price movement expected.

Low importance estimated as earnings releases typically drive at least 1% price movement; GE Aerospace Q2 2026 earnings release and webcast on 2026-07-16 scheduled.

Johnson & Johnson Q2 2026 earnings release and conference call, with low impact estimated as a routine event, scheduled.

Honeywell is scheduled to spin off its Aerospace division into a new, independent, publicly traded company called Honeywell Aerospace (ticker: HONA) on 2026-06-29. The remaining company will be rebranded as Honeywell Technologies (ticker: HON), a major corporate restructuring event expected to significantly impact shareholder value and company focus scheduled.

Micron Technology fiscal third-quarter 2026 financial results announcement scheduled. High importance expected due to historical price volatility of over 10% following earnings releases expected.

Investor Day 2026 in New York City to outline growth and diversification strategy with a focus on AI scheduled. Estimated > 1% impact as it provides long-term strategic clarity.

Quarterly cash dividend of $0.74 per share ex-date on 2026-06-24 scheduled. This is estimated to have a low price impact of approximately 1% based on typical dividend adjustments.

Quarterly dividend of $0.26 per share, announced on May 21, 2026, goes ex-dividend on June 17, 2026.

Ex-dividend date for a quarterly cash dividend of $1.05 per share on 2026-06-15, an increase from the previous $0.90 per share. This dividend increase is estimated to have a low price impact of approximately 1-2%, scheduled.

Meta's quarterly cash dividend of $0.525 per share has an ex-dividend date of June 15, 2026; a price impact of ≥1% is expected.

KLA Corporation confirmed a 10-for-1 forward stock split of its common shares. Shareholders of record on 2026-06-04 receive nine additional shares after the close on 2026-06-11, and KLAC begins trading on a split-adjusted basis on 2026-06-12.

The ex-dividend date for a regular quarterly cash dividend of $1.70 per share on June 12, 2026. The dividend was declared on April 8, 2026, and is payable on July 1, 2026. Market impact is expected to be low as this is a routine corporate action, scheduled.

Adobe is scheduled to release its Q2 fiscal year 2026 earnings results after the market closes on June 11, 2026. Analysts forecast non-GAAP EPS of $5.01, which is below the company's prior guidance of $5.80 to $5.85, creating uncertainty ahead of the release. High importance is estimated based on potential market reaction to the guidance discrepancy, scheduled.

Oracle is scheduled to release its fourth quarter and full fiscal year 2026 financial results after the market close on June 10, 2026, with a conference call to follow. High importance is estimated as earnings releases typically result in significant price volatility, scheduled.

A virtual annual shareholder meeting is scheduled for 2026-06-10; approximately 1% price impact scheduled.

Cloudflare is scheduled to host its 2026 Investor Day at the New York Stock Exchange to provide updates on strategy and financials. This event is estimated to have a 5% price impact as strategic roadmaps are revealed, scheduled.

Apple's Worldwide Developers Conference (WWDC) is scheduled for June 8-12, 2026, featuring major AI strategy announcements and new operating system previews, scheduled. High importance is estimated due to the anticipated impact of the AI strategy overhaul.

Ex-dividend date for a quarterly cash dividend of $0.22 per share, a 5% increase from the prior quarter. The dividend was declared by the Board of Directors on April 27, 2026.

Honeywell is scheduled to host a guidance update call on 2026-06-08 to discuss its 2026 outlook and introduce a preliminary full-year 2026 outlook for Honeywell Technologies scheduled.

Annual Shareholder Meeting scheduled for 2026-06-05, where shareholders are expected to vote on the approval of an annual dividend of $4.20 per share. This routine meeting is estimated to have a price impact of approximately 1%, scheduled.

A quarterly dividend of $1.19 per share is payable on 2026-06-05 to shareholders of record as of 2026-05-15 scheduled.

Ciena is scheduled to report its fiscal second quarter 2026 financial results on June 4, 2026, before the market opens. Analysts forecast EPS of $1.45-$1.46 on revenue of $1.50 billion. High importance is estimated as AI-related earnings often trigger >=10% price movement, scheduled.

Annual Meeting of Stockholders is scheduled for 2026-06-04; Low importance assigned as typical price impact is expected to be at least 1%, scheduled.

Ex-dividend date for the increased quarterly cash dividend of $0.92 per share, payable on June 25, 2026, scheduled for June 4, 2026. Estimated > 1% impact as the dividend amount is significant.

Broadcom is scheduled to release its Q2 2026 earnings results after the market closes on June 3, 2026. Analysts forecast revenue of approximately $22.1 billion and EPS of $2.40, with AI-related revenue expected to be a key focus; high importance is estimated due to historical earnings volatility exceeding 10%, scheduled.

First quarter fiscal year 2027 financial results to be released after market close on June 3, 2026, scheduled. High importance is estimated due to expected significant price movement following the report.

Medtronic's Q4 and full-year fiscal 2026 earnings release is scheduled. Analysts forecast revenue growth but a potential year-over-year decline in earnings per share, forecasted. High importance is estimated due to typical volatility from annual reports, scheduled.

CEO Anirudh Devgan is scheduled to present at the Bank of America (BofA) Securities 2026 Global Technology Conference; low importance due to typically minimal market reaction to such presentations scheduled.

Company executives are scheduled to present at the Evercore Global TMT Conference on June 3, 2026, scheduled. Low impact is estimated as conference presentations typically provide incremental information.

Alphabet announced on June 1/2, 2026, a plan to raise up to $80 billion via stock offerings to fund AI infrastructure investments, citing that customer demand is exceeding its available compute supply. The plan includes a $10 billion private placement to Berkshire Hathaway.

IBM announced plans to invest more than $10 billion in quantum computing over the next five years, covering R&D, manufacturing, M&A, and partnerships to accelerate its quantum roadmap.

CEO Matt Murphy delivered a keynote at COMPUTEX 2026. During the event, NVIDIA CEO Jensen Huang referred to Marvell as the 'next trillion-dollar company,' causing the stock to surge over 20%.

Reported fiscal Q3 2026 earnings with non-GAAP EPS of $0.85, beating estimates, and revenue of $3.0 billion, a 31% year-over-year increase. The company guided for Q4 revenue between $3.345 billion and $3.355 billion. The stock rose over 10% in after-hours trading following the announcement.

Arista's CFO presented at the William Blair 46th Annual Growth Stock Conference, reiterating the company's strong outlook, including its $11.5 billion revenue guidance for 2026 and a raised long-term growth forecast (CAGR) to over 20% for 2025-2028.

CrowdStrike and Cognizant announced an expanded strategic alliance to secure artificial intelligence across its lifecycle. Medium importance is estimated based on the potential for long-term revenue growth from AI security.

The Phase 3 IDEAL study of Livdelzi (seladelpar) met its primary endpoint on June 2, 2026. This clinical success is estimated to have a ≥5% price impact, scheduled.

At its Build 2026 conference on June 2, 2026, Microsoft is scheduled to announce new AI models and the Majorana 2 quantum chip, which is estimated to have a 5% price impact due to major technological advancements scheduled.

Stock price fell 8% on June 2, 2026, following new product and partnership announcements at the company's annual Snowflake Summit event.

Announced on 2026-06-02 that Julie Knecht will be appointed as the new Chief Financial Officer, effective August 1, 2026, succeeding the retiring CFO Rafael Lizardi.

At its Cisco Live 2026 event on June 2, 2026, the company launched a suite of new AI-focused products and platforms, including Cisco Cloud Control and new AI security tools.

Meta announced the global expansion of teen safety settings on June 2, 2026; a price impact of ≥1% is expected.

Russia's Federal Security Service (FSB) accused Cloudflare of involvement in a cyber operation to spy on officials. This event is estimated to have a 1% price impact as geopolitical tensions have limited effect on tech stocks.

Wolfe Research analysts forecast an 'Outperform' rating and a $260 price target on 2026-06-02 estimated.

Reported record Q2 2026 earnings, significantly beating analyst estimates with revenue of $10.7B (up 40% YoY) and non-GAAP EPS of $0.79, driven by strong AI server demand. The company also raised its full-year 2026 guidance and now expects to meet its 2028 long-term financial targets in 2026, two years ahead of schedule.

Announced on June 1, 2026, that its Data Center Solutions Business Unit revenue is expected to grow by approximately 65% to around $500 million in calendar year 2026. The stock rose significantly in after-hours trading.

The European Commission granted marketing authorization for IMDYLLTRA® (tarlatamab) on 2026-06-01 for the treatment of ES-SCLC; expected to have a medium market impact of approximately 5% due to expanded market access.

Biogen and partner UCB announced that their Phase 3 PHOENYCS GO clinical trial for dapirolizumab pegol met its primary endpoint; a 5-10% price impact is estimated as Phase 3 success in a major indication is a significant catalyst, scheduled.

The US FDA accepted the Biologics License Application (BLA) for povetacicept for the treatment of IgA nephropathy (IgAN) on June 1, 2026. This is estimated to have a medium market impact as a significant regulatory milestone. The agency set a PDUFA target action date of November 30, 2026, scheduled.

Citigroup reaffirmed its 'buy' rating on AppLovin stock with a price target of $710.00 forecasted. Low impact estimated as analyst rating reaffirmations generally result in minor market adjustments.

The Board of Directors declared a regular quarterly cash dividend of $0.1425 per share, payable around July 15, 2026, to stockholders of record as of June 16, 2026.

Announced on June 1, 2026, plans to implement selective price increases across its product portfolio due to rising input costs, stating it will not affect guidance for the quarter ending June 30, 2026. Low impact is estimated as the company stated this will not affect current quarter guidance.

CEO Cristiano Amon keynote at Computex 2026, outlining the company's AI strategy and introducing the 'Dragonfly' brand, scheduled. Estimated > 1% impact due to new brand introduction.

U.S. government extended export license rules for advanced AI chips, including AMD's MI350x, to Chinese-owned firms located outside of China, closing a perceived loophole.

Johnson & Johnson announced positive results from the Phase 1b/2 OrigAMI-4 clinical trial for amivantamab in treating advanced head and neck cancer, showing a 42% overall response rate in heavily pretreated patients.

Announced new consumer products at Computex 2026, including the Ryzen 7 7700X3D CPU and the global launch of the Radeon RX 9070 GRE GPU, and extended AM5 platform support through 2029.

Tesla resolved a supply dispute with Syrah Resources on May 31, 2026, by withdrawing a default notice related to a graphite supply agreement. This resolution secures a domestic US source for battery anode material. A low impact is estimated due to supply chain stabilization, scheduled.

Biogen and Denali announced the discontinuation of BIIB122 for Parkinson's disease on May 29, 2026; a 5-10% price impact is estimated due to the loss of a mid-stage candidate, scheduled.

Scheduled to announce privately-negotiated agreements on 2026-05-29 to exchange approximately $650.4 million of its 0.50% Convertible Senior Notes due 2028 for approximately 5.0 million shares of common stock. Medium importance is estimated as the positive impact of debt reduction is likely offset by share dilution, potentially leading to a 5-10% price impact; scheduled.

Oracle's stock price increased significantly following the announcement of a substantial cloud infrastructure agreement with the US government, positioning the company as a key provider of AI computing capacity for national security.

Multiple analysts raised price targets in late May 2026 following strong earnings, with Susquehanna increasing its target to $3,250 on May 29, 2026, forecasted. Medium importance as target raises typically drive 5-10% price movement.

Amazon continued to reduce its workforce in May 2026 across AWS, Prime Video, and other divisions, following major layoffs earlier in the year, as part of a broader restructuring and efficiency plan.

CrowdStrike announced it was named a Leader in the 2026 Gartner® Magic Quadrant™ for Endpoint Protection Platforms for the seventh consecutive time. Low importance is estimated as this recognition is largely anticipated by the market.

The FDA granted Breakthrough Therapy Designation for the investigational KRAS G12C inhibitor calderasib (MK-1084) on May 29, 2026.

Scheduled to announce a collaboration with Diakonos Oncology for a Phase I/II clinical trial on 2026-05-29; Low importance due to expected >1% price impact from clinical collaboration scheduled.

Axon's stock price surged over 12% on May 28, 2026, attributed to investor confidence following its annual shareholder meeting, a presentation at the TD Cowen TMT conference, and a delayed positive reaction to its strong Q1 earnings report.

CrowdStrike announced the expansion of its Project QuiltWorks, adding major cyber insurers like Coalition and Liberty Mutual to address financial exposure to frontier AI risk. Medium importance is estimated due to the strategic entry into AI-related insurance.

Completed the divestiture of its remaining 19% stake in H3C Technologies Co., Limited, receiving cash proceeds of approximately $1.357 billion.

IBM and Red Hat announced Project Lightwell, a $5 billion commitment to help enterprises secure open source software using AI and a global team of over 20,000 engineers.

RTX, with partner Northrop Grumman, received a DARPA Phase 2 contract to develop modular and composable solid rocket motors to accelerate munitions production.

Tesla was granted authorization by the State of Texas to operate driverless vehicles commercially, effective May 28, 2026. This allows the company to self-certify its autonomous vehicles for commercial robotaxi services under a new state law. A medium impact is estimated as this opens a significant new revenue stream, scheduled.

Axon held its 2026 Annual Meeting of Shareholders on May 28, 2026. Shareholders elected nine directors, approved executive compensation on an advisory basis, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor.

At the 2026 Annual Meeting of Stockholders on May 28, 2026, the company's stockholders approved an amendment to the 2013 Equity Incentive Plan, increasing the number of shares reserved for issuance by 34 million. Low importance is assigned as this is a routine administrative update with minimal immediate market impact.

The FDA approved a label expansion for TREMFYA® (guselkumab) for the treatment of adults with active psoriatic arthritis, making it the only IL-23 inhibitor with an indication for inhibiting the progression of structural damage.